Niknamian, S. | bioRxiv Science

bioRxiv2019

Effects of high iodine containing low osmolar contrast agent (visipaque) on thyroid function tests

ObjectiveInvestigating high iodine containing low osmolar contrast agent (visipaque) effects on thyroid function tests and thyroid sonography characteristics. Methods65 euthyroid cases and 92 controls composed the samples in the baseline. Thyroid function tests, Urine Iodine Concentration (UIC) and thyroid sonography were conducted for both groups before and 1 and 3 months after angiography. Serum levels of T4, T3, T3RU, TSH, TPO-Ab, and UIC were measured, and hypo/hyperthyroidism prevalence was compared between groups. ResultsMean T3, T4 and TSH change 1 month after angiography were insignificant in both groups (P:0.61, P:0.4 and P:0.14, P:0.23 in cases and controls for T3 and T4). Medians among cases and controls were 12.8 and 16.75 g/dl, respectively, at baseline. These values varied to 28.45 and 15.2g/dl, and 12.95 and 14.2g/dl 1 month and 3 months after angiography in case and control groups, respectively. UIC increase one month after angiography was significant among cases (P=0.002). TPO-Ab+ were same 3 months after angiography. Thyroid volume changes were significant among cases (P<0.001) and insignificant among controls (P=0.680). No significant difference was seen between cases and controls in overt hypothyroidism, however, a considerable change was seen in thyroid volume and UIC one month after angiography among cases. The hypothyroidism rate among cases was insignificant which may be either related to few cases or short half-life of visipaque (2.1 hours) so that 97% of the injected dose was excreted in urine within 24 hours. ConclusionThyroid function test is not recommended before angiography in patients without previous thyroid records.

pathology↗

bioRxiv2018

OCT4 expression regulated apoptosis and cell cycle in myeloma cells

PurposeOCT4 gene is specifically expressed in embryonic stem cells and plays a very important role in the proliferation, differentiation, and self-renewal of these cells. The abnormal expression of the OCT4 gene has been observed in most malignancies. Expression of this gene can affect the proliferation and apoptosis of malignant cells by activating various signaling pathways. The proliferation and excessive accumulation of myeloma cells in the bone marrow causes the essential complications of multiple myeloma. Genetic changes and mutations play a role in unscheduled proliferation and diminishing of the apoptosis of the myeloma cells. Material and methodsIn this study, the expression of the OCT4 gene by quantitative PCR and its effects on proliferation, apoptosis, and cell cycle of the myeloma cells by flow cytometry was investigated. ResultsThe results of our study indicated that the myeloma cells express the OCT4 gene; and inhibition of the OCT4 gene by siRNA reduced its expression. The siRNA treated myeloma cells indicated decreased proliferation and increased apoptosis. ConclusionAs with studies in other malignancies, our study also revealed that the OCT4 gene was expressed in the myeloma cells, with evidences of increased proliferation and reduced apoptosis in these cells.

cancer biology↗